Observations placeholder
Simulect
Identifier
020032
Type of Spiritual Experience
Number of hallucinations: 13
Background
A description of the experience
Basiliximab (trade name Simulect) is a chimeric mouse-human monoclonal antibody to the α chain (CD25) of the IL-2 receptor of T cells. It is used to prevent rejection in organ transplantation, especially in kidney transplants. It was approved by the Food and Drug Administration (FDA) in 1998.
Basiliximab is an immunosuppresant used to prevent immediate transplant rejection in people who are receiving kidney transplants, in combination with other agents.
On Feb, 8, 2016: 2,178 people reported to have side effects when taking Simulect. Among them, 13 people (0.60%) have Hallucination.
Time on Simulect when people have Hallucination :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Hallucination | 76.92% | 15.38% | 7.69% | 0.00% | 0.00% | 0.00% | 0.00% |
Gender of people who have Hallucination when taking Simulect :
| Female | Male | |
| Hallucination | 0.00% | 100.00% |
Age of people who have Hallucination when taking Simulect :
| 0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
| Hallucination | 0.00% | 0.00% | 0.00% | 0.00% | 7.14% | 85.71% | 0.00% | 7.14% |
On Jan, 23, 2016: 2,178 people reported to have side effects when taking Simulect. Among them, 19 people (0.87%) have Death.
Time on Simulect when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 90.00% | 0.00% | 10.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Gender of people who have Death when taking Simulect :
| Female | Male | |
| Death | 45.83% | 54.17% |
Age of people who have Death when taking Simulect :
| 0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
| Death | 0.00% | 0.00% | 0.00% | 11.76% | 23.53% | 23.53% | 0.00% | 41.18% |
Top conditions involved for these people :
- Renal transplant (15 people, 78.95%)
- Cytomegalovirus test positive (2 people, 10.53%)
- Chronic obstructive pulmonary disease (1 people, 5.26%)
- Heart transplant (1 people, 5.26%)
- Liver transplant (1 people, 5.26%)